Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
Aclaris Therapeutics (NASDAQ: ACRS) announced participation in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 11, 2022, at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) announced participation in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 11, 2022, at 9:00 a.m. ET. President and CEO Dr. Neal Walker and Consultant Walter Smith will discuss the company’s initiatives in developing novel drug candidates for immuno-inflammatory diseases. The chat will be accessible via Aclaris’ website and archived for 30 days. Aclaris is focused on innovative treatments for patients with unmet medical needs in immuno-inflammatory diseases.
Details
News Market Reaction – ACRS
The recorded move for ACRS in the trading session of this news was +0.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith, Scientific and Business Development Consultant, of Aclaris will participate in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on Wednesday, May 11, 2022 at 9:00 a.m. ET.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Contact
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.